Anavex Life Sciences Corp. (AVXL): Price and Financial Metrics


Anavex Life Sciences Corp. (AVXL)

Today's Latest Price: $5.25 USD

0.10 (1.94%)

Updated Oct 22 4:00pm

Add AVXL to Watchlist
Sign Up

Overall POWR Rating

Sign Up to See Ratings...FREE!

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

AVXL Stock Price Chart Interactive Chart >

Price chart for AVXL

AVXL Price/Volume Stats

Current price $5.25 52-week high $6.31
Prev. close $5.15 52-week low $2.20
Day low $5.04 Volume 659,100
Day high $5.32 Avg. volume 946,659
50-day MA $4.30 Dividend yield N/A
200-day MA $3.94 Market Cap 316.00M

Anavex Life Sciences Corp. (AVXL) Company Bio

Anavex Life Sciences Corporation is engaged in the discovery and development of drugs for the treatment of Alzheimer’s disease, central nervous system diseases, and pain and various cancers. The company was founded in 2006 and is based in New York, New York.

Most Popular Stories View All

• Dangerous Outlook for Stocks Into Election

• Forget FAAMG, Buy These 4 Top Stocks Instead

• Is Electric Vehicle Stock Workhorse Group a Buy at $20?

• 4 Innovative ETFs to SUPERPOWER Your Portfolio in 2021

• Aurora Cannabis vs. Canopy Growth: Which Stock is a Better Buy?

View All Top Stories

AVXL Latest News Stream

Event/Time News Detail
Loading, please wait...
View All AVXL News

AVXL Latest Social Stream

Loading social stream, please wait...

View Full AVXL Social Stream

Latest AVXL News From Around the Web

Below are the latest news stories about Anavex Life Sciences Corp that investors may wish to consider to help them evaluate AVXL as an investment opportunity.

Satsuma Migraine Failure, And Other News: The Good, Bad And Ugly Of Biopharma

Satsuma reports disappointing top-line data for Phase 3 trial Satsuma Pharmaceuticals, Inc. (STSA) reported top-line results from its EMERGE efficacy trial assessing STS101 powder as an acute treatment for migraine. The top-line data showed favorable numerical differences for STS101 3.9 mg and 5.2 mg versus placebo on the pre-specified co-primary...

Avisol Capital Partners on Seeking Alpha | September 14, 2020

Anavex Life Sciences Corp. (AVXL) CEO Dr. Christopher Missling on Q3 2020 Results - Earnings Call Transcript

Anavex Life Sciences Corp. (AVXL) Q3 2020 Results Conference Call August 06, 2020 11:00 AM ET Company Participants Clint Tomlinson - IR Dr. Christopher Missling - President and CEO Sandra Boenisch - Principal Financial Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Edward Marks - H.C. Wainwright Presentation Operator...

SA Transcripts on Seeking Alpha | August 9, 2020

Anavex Life Sciences Reports Fiscal 2020 Third Quarter Financial Results And Provides Business Updates

NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company …

Benzinga | August 6, 2020

Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX®2-73 (blarcamesine) for Alzheimer’s Disease Patients

Compassionate Use Special Access Scheme Approval for Alzheimer’s Patients to Continue Treatment with ANAVEX®2-73 (blarcamesine) after Completing the 5-Year ANAVEX®2-73-003 Phase 2a Clinical Study

GlobeNewswire | August 5, 2020

Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)

NEW YORK, July 06, 2020 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated.

Yahoo | July 6, 2020

Read More 'AVXL' Stories Here

AVXL Price Returns

1-mo 34.62%
3-mo 18.78%
6-mo 55.79%
1-year 93.01%
3-year 11.46%
5-year -31.37%
YTD 102.70%
2019 66.03%
2018 -51.55%
2017 -18.69%
2016 -28.90%
2015 652.70%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.4272 seconds.